Amedeo Smart

Free Medical Literature Service

 

Amedeo

Leukemia
  Free Subscription

11.03.2024

1 Acta Haematol
2 Am J Hematol
3 Ann Hematol
9 Blood
1 Bone Marrow Transplant
1 Br J Cancer
2 Cancer Chemother Pharmacol
2 Int J Hematol
3 J Clin Oncol
2 J Pediatr Hematol Oncol
3 Leuk Res
8 Leukemia
1 Proc Natl Acad Sci U S A


    Acta Haematol

  1. MORIGUCHI M, Ido K, Okamura H, Nakamae M, et al
    Impacts of Posttransplant Cyclophosphamide Dose on Graft-versus-leukemia Effects via HLA-B Leader in HLA-haploidentical Peripheral Blood Stem Cell Transplantation.
    Acta Haematol. 2024 Mar 1. doi: 10.1159/000538078.
    >> Share


    Am J Hematol

  2. PATNAIK MM, Tefferi A
    Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.
    Am J Hematol. 2024 Mar 7. doi: 10.1002/ajh.27271.
    >> Share

  3. TROUSSARD X, Maitre E, Paillassa J
    Hairy cell leukemia 2024: Update on diagnosis, risk-stratification, and treatment-Annual updates in hematological malignancies.
    Am J Hematol. 2024 Mar 5. doi: 10.1002/ajh.27240.
    >> Share


    Ann Hematol

  4. OU J, Deng S, Ding C, Cai Z, et al
    Mutations of epigenetic modifier genes predict poor outcome in adult acute lymphoblastic leukemia.
    Ann Hematol. 2024 Mar 7. doi: 10.1007/s00277-024-05681.
    >> Share

  5. RORVIK SD, Torkildsen S, Bruserud O, Tvedt THA, et al
    Acute myeloid leukemia with rare recurring translocations-an overview of the entities included in the international consensus classification.
    Ann Hematol. 2024 Mar 6. doi: 10.1007/s00277-024-05680.
    >> Share

  6. DARTIGEAS C, Quinquenel A, Ysebaert L, Dilhuydy MS, et al
    Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study.
    Ann Hematol. 2024 Mar 6. doi: 10.1007/s00277-024-05666.
    >> Share


    Blood

  7. O'CONNOR D, Valle-Inclan JE, Conde L, Bloye G, et al
    Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL.
    Blood. 2024;143:933-937.
    >> Share

  8. BARROS PINTO MP, Cabecadas J
    Binucleated and cloverleaf-shaped nucleus in lymphocytes in CLL.
    Blood. 2024;143:833.
    >> Share

  9. MENSURADO S, Condeco AC, Sanchez-Martinez D, Shirley S, et al
    CD155/PVR determines Acute Myeloid Leukemia targeting by Delta One T cells.
    Blood. 2024 Feb 16:blood.2023022992. doi: 10.1182/blood.2023022992.
    >> Share

  10. AVILA AVILA A, Nuantang K, Oliveira ML, Druillennec S, et al
    Targeting the TNF/IAP pathway synergizes with anti-CD3 immunotherapy in T-Cell Acute Lymphoblastic Leukemia.
    Blood. 2024 Mar 4:blood.2023022455. doi: 10.1182/blood.2023022455.
    >> Share

  11. ESCHERICH CS, Chen W, Li Y, Yang W, et al
    Germline Genetic NBN Variation and Predisposition to B-cell Acute Lymphoblastic Leukemia in Children.
    Blood. 2024 Mar 6:blood.2023023336. doi: 10.1182/blood.2023023336.
    >> Share

  12. AHMED R, Feldman AL
    Occult ALK-negative anaplastic large cell lymphoma complicating chronic lymphocytic leukemia.
    Blood. 2024;143:938.
    >> Share


  13. Colom Diaz PA, Mistry JJ, Trowbridge JJ. Hematopoietic stem cell aging and leukemia transformation. Blood. 2023;142(6):533-542.
    Blood. 2024;143:939.
    >> Share

  14. CHALANDON Y, Rousselot P, Chevret S, Cayuela JM, et al
    Nilotinib with or without cytarabine for Philadelphia positive acute lymphoblastic leukemia.
    Blood. 2024 Mar 7:blood.2023023502. doi: 10.1182/blood.2023023502.
    >> Share

  15. FELIPE FUMERO E, Walter C, Frenz JM, Seifert FC, et al
    Epigenetic control over cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia.
    Blood. 2024 Mar 8:blood.2023021640. doi: 10.1182/blood.2023021640.
    >> Share


    Bone Marrow Transplant

  16. PARK S, Bang SY, Kwag D, Lee JH, et al
    Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1.
    Bone Marrow Transplant. 2024 Mar 4. doi: 10.1038/s41409-024-02255.
    >> Share


    Br J Cancer

  17. LITTLE MP, Eidemuller M, Kaiser JC, Apostoaei AI, et al
    Minimum latency effects for cancer associated with exposures to radiation or other carcinogens.
    Br J Cancer. 2024;130:819-829.
    >> Share


    Cancer Chemother Pharmacol

  18. DILLI BATCHA JS, Gota V, Matcha S, Raju AP, et al
    Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients.
    Cancer Chemother Pharmacol. 2024 Mar 5. doi: 10.1007/s00280-024-04644.
    >> Share

  19. QU W, Lu J, Ji Y, He Z, et al
    Successful use of Palbociclib combined with Venetoclax and Azacitidine in an adult with refractory/relapsed therapy-related acute myeloid leukemia.
    Cancer Chemother Pharmacol. 2024 Mar 2. doi: 10.1007/s00280-024-04642.
    >> Share


    Int J Hematol

  20. AN K, He Y, Tang Y, Gu X, et al
    Histiocytic sarcoma following CAR T-cell therapy: a case report.
    Int J Hematol. 2024;119:338-341.
    >> Share

  21. XUE S, Sun HP, Huang XB, Chen X, et al
    Characteristics and literature review of ETV6::ABL1 fusion gene-positive acute myeloid leukemia.
    Int J Hematol. 2024 Mar 5. doi: 10.1007/s12185-024-03729.
    >> Share


    J Clin Oncol

  22. FOA R, Bassan R, Elia L, Piciocchi A, et al
    Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL.
    J Clin Oncol. 2024;42:881-885.
    >> Share

  23. CONTER V, Valsecchi MG, Cario G, Zimmermann M, et al
    Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study.
    J Clin Oncol. 2024;42:915-926.
    >> Share

  24. HODDER A, Mishra AK, Enshaei A, Baird S, et al
    Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL.
    J Clin Oncol. 2024;42:907-914.
    >> Share


    J Pediatr Hematol Oncol

  25. SADANAND A, Patel P, Riedesel E, Berkowitz F, et al
    Bartonella henselae Infection and Lymphadenopathy in a Patient With T Cell Acute Lymphoblastic Leukemia.
    J Pediatr Hematol Oncol. 2024 Feb 29. doi: 10.1097/MPH.0000000000002844.
    >> Share

  26. CHAUDHARY S, Chaudhary P, Ahmad F, Arora N, et al
    Acute Myeloid Leukemia and Next-Generation Sequencing Panels for Diagnosis: A Comprehensive Review.
    J Pediatr Hematol Oncol. 2024 Feb 29. doi: 10.1097/MPH.0000000000002840.
    >> Share


    Leuk Res

  27. OSMAN AEG, Rets A, Patel AB
    KRAS mutations, autoimmunity and female sex in chronic myelomonocytic leukemia.
    Leuk Res. 2024;138:107466.
    >> Share

  28. SANCHEZ-PETITTO G, Goloubeva OG, Masur J, Childress J, et al
    Clinical outcomes of patients with acute myeloid leukemia and cardiovascular disease.
    Leuk Res. 2024;138:107456.
    >> Share

  29. SUDO H, Tonoyama Y, Ikebe E, Hasegawa H, et al
    Proteomic analysis of adult T-cell leukemia/lymphoma: A biomarker identification strategy based on preparation and in-solution digestion methods of total proteins.
    Leuk Res. 2024;138:107454.
    >> Share


    Leukemia

  30. CHEN CC, Silberman RE, Ma D, Perry JA, et al
    Inherent genome instability underlies trisomy 21-associated myeloid malignancies.
    Leukemia. 2024;38:521-529.
    >> Share

  31. SANZ-ORTEGA L, Andersson A, Carlsten M
    Harnessing upregulated E-selectin while enhancing SDF-1alpha sensing redirects infused NK cells to the AML-perturbed bone marrow.
    Leukemia. 2024;38:579-589.
    >> Share

  32. PARRIOTT G, Hegermiller E, Morman RE, Frank C, et al
    Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T-ALL.
    Leukemia. 2024;38:491-501.
    >> Share

  33. SPINELLA JF, Chagraoui J, Moison C, Lavallee VP, et al
    DELE1 haploinsufficiency causes resistance to mitochondrial stress-induced apoptosis in monosomy 5/del(5q) AML.
    Leukemia. 2024;38:530-537.
    >> Share

  34. BIRDWELL CE, Fiskus W, Kadia TM, Mill CP, et al
    Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
    Leukemia. 2024;38:545-556.
    >> Share

  35. MA J, Liu YC, Voss RK, Ma J, et al
    Genomic and global gene expression profiling in pediatric and young adult acute leukemia with PICALM::MLLT10 Fusion.
    Leukemia. 2024 Mar 1. doi: 10.1038/s41375-024-02194.
    >> Share

  36. PERUSINI MA, Andrews C, Eshetu AG, Gupta V, et al
    Asparaginase completion among adults including older patients with acute lymphoblastic leukemia treated with a modified DFCI protocol.
    Leukemia. 2024 Mar 2. doi: 10.1038/s41375-024-02201.
    >> Share

  37. THOMAS ME 3RD, Qi W, Walsh MP, Ma J, et al
    Functional characterization of cooperating MGA mutations in RUNX1::RUNX1T1 acute myeloid leukemia.
    Leukemia. 2024 Mar 7. doi: 10.1038/s41375-024-02193.
    >> Share


    Proc Natl Acad Sci U S A

  38. KATSUMURA KR, Liu P, Kim JA, Mehta C, et al
    Pathogenic GATA2 genetic variants utilize an obligate enhancer mechanism to distort a multilineage differentiation program.
    Proc Natl Acad Sci U S A. 2024;121:e2317147121.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016